GSK Patent-Cliff Exposure & CMS Drug Spending Portfolio

GSK (Philadelphia, PA): 71 reconciled FDA prescription therapies (60.6% 2025 to 2030 cliff risk), $16.94B 2024 CMS Part D & Medicaid spend, and 67 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterPhiladelphia, PA
Reconciled FDA Portfolio Therapies71
2025 to 2030 Patent-Cliff Revenue Exposure60.6%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$16.94B
2024 Medicare Part D Spend$13.84B
2024 Medicaid Spend$3.10B
California HCAI SB 17 Filings67 WAC filings (max 28.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.